Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE:ONCO)

1.490 -0.090 (-5.70%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,616
Open 1.540
Bid (Size) 1.400 (300)
Ask (Size) 1.490 (900)
Prev. Close 1.580
Today's Range 1.400 - 1.540
52wk Range 0.5600 - 2.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
Via ACCESS Newswire
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
Via ACCESS Newswire

Performance

YTD
+75.3%
+75.3%
1 Month
-6.9%
-6.9%
3 Month
-35.2%
-35.2%
6 Month
+148.3%
+148.3%
1 Year
+148.3%
+148.3%

More News

Read More
Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology
Via ACCESS Newswire
Onco-Innovations Announces Private Placement
Via ACCESS Newswire
Onco-Innovations' Private Placement Fully Subscribed
Via ACCESS Newswire
Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research
Via ACCESS Newswire
Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
Via ACCESS Newswire
Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Via ACCESS Newswire
Onco-Innovations Extends Marketing Program
Via ACCESS Newswire
Onco-Innovations Provides Update on Use of Proceeds
Via ACCESS Newswire
Onco-Innovations CEO Thomas O’Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
Via ACCESS Newswire
Onco-Innovations' Inka Health Innovative AI-Driven Oncology Study Paves the Way for New Research
Via ACCESS Newswire
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Via ACCESS Newswire
Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph
Via ACCESS Newswire
Onco-Innovations Announces U.S. Listing on the OTCQB Market
Via ACCESS Newswire
Onco-Innovations' Nanoparticle Formulation PNKP Technology Combined with Radiation Therapy, and as a Standalone Treatment, Shown in Studies to Slow Colorectal Cancer Tumour Growth
Via ACCESS Newswire
Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study
Via ACCESS Newswire
Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research
Via ACCESS Newswire
Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development
Via ACCESS Newswire
Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair
Via ACCESS Newswire
Onco-Innovations Unaware of Any Material Change
Via ACCESS Newswire
Onco-Innovations Enters into LOI with Inka Health to Implement AI Technology Toward Cancer Detection and Drug Development
Via ACCESS Newswire
Onco-Innovations' Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells
Via ACCESS Newswire
Onco-Innovations' Technology Shown in Study to Successfully Inactivate DNA Repair in Cancer, Potentially Boosting Radiation Therapy Effectiveness
Via ACCESSWIRE
Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options
Via ACCESSWIRE

Frequently Asked Questions

Is ONCO publicly traded?
Yes, ONCO is publicly traded.
What exchange does ONCO trade on?
ONCO trades on the Canadian Securities Exchange
What is the ticker symbol for ONCO?
The ticker symbol for ONCO is ONCO on the Canadian Securities Exchange
What is the current price of ONCO?
The current price of ONCO is 1.490
When was ONCO last traded?
The last trade of ONCO was at 05/16/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.